📰 Valency Communications News
Page 3 - Valency Communications News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valency Communications. Real-time updates on events, politics, business and more.
March 29, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 29, 2023
March 28, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 28, 2023
March 27, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 27, 2023
March 23, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 23, 2023
March 7, 2023
07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk ...
December 7, 2022
07.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of the ADVANCE II trial in AML maintenance, which ...
December 5, 2022
05.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: 64th Annual Society of ...
October 26, 2022
The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the extraordinary general meeting (“EGM”) on Friday, 18...
October 18, 2022
TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced an agreement to... | October 18, 2022
October 17, 2022
RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION Mendus AB (“Mendus” publ;...